Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

INHERITED CANCER GENETICS

Cardiff and Vale University Health Board

This public procurement record has 3 releases in its history.

Award

09 Jul 2026 at 08:23

UK7 - Contract Details Notice
Award

25 Jun 2026 at 12:15

UK6 - Contract Award Notice
Award

25 Jun 2026 at 11:46

UK5 - Transparency Notice
Summary of the contracting process

The recent procurement process by Cardiff and Vale University Health Board involves an awarded contract for inherited cancer genetic testing services. The service is crucial for supporting the All Wales Medical Genomics Service by providing timely and accurate diagnostic testing across Wales, which addresses ongoing capacity constraints in in-house laboratory services. The contracting authority, located in Cardiff, Wales, opted for a direct award to "Informed Genetics," a Birmingham-based supplier, due to the necessity of maintaining service continuity and avoiding operational risks. The contract, valued at £540,000, is scheduled to commence on 1 January 2027 and conclude on 31 December 2027. The procurement method chosen was a direct award, considering the supplier's technical capabilities and existing integration with clinical pathways.

This tender creates significant opportunities for businesses involved in specialised medical analysis and diagnostic services, particularly those equipped with established infrastructure, accredited laboratory processes, and a deep understanding of clinical pathways. Businesses with technical expertise and capability in genetic testing, particularly those familiar with proprietary systems and workflows, would be well-positioned to compete in similar future procurements. Additionally, companies looking to expand into the Welsh healthcare market or those capable of managing complex diagnostic workloads would find participating in such tenders beneficial for business growth.

How relevant is this notice?

Notice Information

Notice Title

INHERITED CANCER GENETICS

Notice Description

Cardiff and Vale University Health Board intends to award a contract for the provision of outsourced inherited cancer genetic testing services to a single supplier.This service is critical to supporting the All Wales Medical Genomics Service (AWMGS), ensuring continued access to timely and accurate diagnostic testing across Wales. Ongoing capacity constraints within in-house laboratory services, combined with sustained clinical demand, require the continuation of outsourced provision to maintain turnaround times and support patient care pathways.The selected supplier is already embedded within the service and has demonstrated the capability and capacity to deliver the required testing to the necessary quality standards. Maintaining this arrangement ensures continuity of service and avoids disruption to established clinical pathways.Introducing an alternative supplier at this stage would present significant operational and clinical risks, including delays to patient diagnosis, disruption to workflows, and additional onboarding and validation requirements.Awarding to a sole supplier is therefore considered necessary to ensure continuity of critical services, protect patient safety, and support ongoing service delivery.

Procurement Information

Single supplier - technical reasons The requirement relates to a highly specialised clinical service for inherited cancer genetic testing, which requires specific technical capability, accredited laboratory processes, and integration with existing clinical pathways. The identified supplier has the necessary infrastructure, validated methodologies, and established interfaces with the All Wales Medical Genomics Service (AWMGS), enabling continuity of testing, reporting, and data management. These technical requirements cannot be readily replicated by alternative suppliers within the required timeframe without significant disruption. Furthermore, the supplier's ability to deliver within existing turnaround times, manage current demand, and support backlog recovery is dependent on proprietary systems, validated workflows, and specialist expertise. Transitioning to an alternative supplier would necessitate duplication of validation processes, interface development, and clinical assurance activity, introducing unacceptable operational and clinical risk. Single supplier - unique work of art or performance (proprietary justification) The service provision is considered proprietary in nature due to the supplier's established integration within the current service model, including embedded processes, reporting mechanisms, and clinical pathways specific to AWMGS requirements. The supplier is already delivering testing services aligned to the Health Board's specifications, with proven performance in managing complex and high-volume diagnostic workloads. Their service includes unique elements such as established data flows, validated testing protocols, and familiarity with Welsh clinical pathways, which collectively form a bespoke service offering that is not readily transferable. Any change in supplier would require significant revalidation of testing processes, redevelopment of interfaces, and onboarding of clinical pathways, which would disrupt service delivery and delay patient diagnosis. This establishes the supplier as the only provider capable of delivering the required service without interruption, therefore justifying a sole supplier award on the basis of proprietary service delivery.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06bcee
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/064441-2026
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services

CPV Codes

85148000 - Medical analysis services

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£450,000 £100K-£500K
Contracts Value
£450,000 £100K-£500K

Notice Dates

Publication Date
9 Jul 20262 months ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
24 Jun 20262 months ago
Contract Period
1 Jan 2027 - 31 Dec 2027 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
Cardiff and Vale University Health Board
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
CARDIFF
Postcode
CF14 4HH
Postcode Area
Cardiff
Country
Wales
Major Region (ITL 1)
TLL Wales
Basic Region (ITL 2)
TLL5 South East Wales
Small Region (ITL 3)
TLL52 Cardiff and Vale of Glamorgan
Delivery Location
Not specified
Local Authority
Cardiff
Electoral Ward
Heath
Westminster Constituency
Cardiff North

Supplier Information

Number of Suppliers
1
Supplier Name

Informed Genomics Ltd

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...